RT Journal Article
SR Electronic
T1 A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP 197
DO 10.1186/s40425-019-0680-3
VO 7
IS 1
A1 Zimmer, Alexandra S.
A1 Nichols, Erin
A1 Cimino-Mathews, Ashley
A1 Peer, Cody
A1 Cao, Liang
A1 Lee, Min-Jung
A1 Kohn, Elise C.
A1 Annunziata, Christina M.
A1 Lipkowitz, Stanley
A1 Trepel, Jane B.
A1 Sharma, Rajni
A1 Mikkilineni, Lekha
A1 Gatti-Mays, Margaret
A1 Figg, William D.
A1 Houston, Nicole D.
A1 Lee, Jung-Min
YR 2019
UL http://jitc.bmj.com/content/7/1/197.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.